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Abstract 
Background: The emergence of drug resistance in Plasmodium falciparum has been a major contributor to the 
global burden of malaria. Drug resistance complicates treatment, and it is one of the most important problems in 
malaria control. This study assessed the level of mutations in P. falciparum genes, pfdhfr, pfdhps, pfmdr1, and pfcrt, 
related to resistance to different anti‑malarial drugs, in the Continental Region of Equatorial Guinea, after 8 years of 
implementing artesunate combination therapies as the first‑line treatment.
Results: A triple mutant of pfdhfr (51I/59R/108N), which conferred resistance to sulfadoxine/pyrimethamine (SP), 
was found in 78% of samples from rural settings; its frequency was significantly different between urban and rural 
settings (p = 0.007). The 164L mutation was detected for the first time in this area, in rural settings (1.4%). We 
also identified three classes of previously described mutants and their frequencies: the partially resistant (pfdhfr 
51I/59R/108N + pfdhps 437G), found at 54% (95% CI 47.75–60.25); the fully resistant (pfdhfr 51I/59R/108N + pfdhps 
437G/540E), found at 28% (95% CI 7.07–14.93); and the super resistant (pfdhfr 51I/59R/108N + pfdhps 
437G/540E/581G), found at 6% (95% CI 0.48–4.32). A double mutation in pfmdr1 (86Y + 1246Y) was detected at 2% 
(95% CI 0.24–3.76) frequency, distributed in both urban and rural samples. A combination of single mutations in the 
pfmdr1 and pfcrt genes (86Y + 76T), which was related to resistance to chloroquine and amodiaquine, was detected 
in 22% (95% CI 16.8–27.2) of samples from the area.
Conclusions: The high level of mutations detected in P. falciparum genes related to SP resistance could be linked 
to the unsuccessful withdrawal of SP treatment in this area. Drug resistance can reduce the efficacy of intermittent 
prophylactic treatment with SP for children under 5 years old and for pregnant women. Although a high number of 
mutations was detected, the efficacy of the first‑line treatment, artemisinin/amodiaquine, was not affected. To avoid 
increases in the numbers, occurrence, and spread of mutations, and to protect the population, the Ministry of Health 
should ensure that health centres and hospitals are supplied with appropriate first‑line treatments for malaria.
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Background
Equatorial Guinea is located in Central West Africa. The 
country has two regions, the Continental Region (Rio 
Muni) and the Insular Region (Bioko, Annobon) (Fig. 1). 
Malaria remains a major public health problem in the 
country. It is a holo-endemic area with a year-round 
transmission pattern [1]. The prevalence of malaria was 
more than 1 case per 1000 people in the population in 
2013; the last data published reported 13,000 malaria 
cases and 66 malaria-related deaths. Malaria in Equato-
rial Guinea caused 15% of deaths among children under 
5 years of age in 2013. In 2014, positive malaria samples 
reached a frequency of 36% [2].
In 2011, in the continental region, 95.2% of malaria 
cases were caused by Plasmodium falciparum and 9.5% 
were caused by Plasmodium vivax. Moreover, eight cases 
were caused by mixed infections of P. falciparum and P. 
vivax [3]. According to the most recent World Health 
Organization (WHO) Malaria Report, the prevalence of 
malaria was 36% in Equatorial Guinea [2].
The emergence of drug resistance, particularly among 
P. falciparum parasites, has been a major contributor 
to the global burden of malaria in the past three dec-
ades [4]. Resistance is the most likely explanation for 
the doubling of malaria-attributable child mortality in 
eastern and southern Africa [5]. In general terms, P. fal-
ciparum drug resistance has become widespread around 
the world, and this fact makes its treatment difficult. 
Moreover, P. falciparum drug resistance is one of the 
most important problems in malaria control, due to the 
increasing resistance to almost all anti-malarial drugs, 
including amodiaquine (AQ), chloroquine (CQ), meflo-
quine, artemether–lumefantrine, sulfadoxine/pyrimeth-
amine (SP), and recently, artemisinin. Molecular markers 
that can detect anti-malarial drug resistance comprise 
one of the most valuable methods in screening for anti-
malarial drugs. Markers can predict the efficacy and 
resistance to anti-malarial drugs, and indicate emerging 
resistance in a determined area [6].
The resistance to different anti-malarial drugs is due 
to single nucleotide polymorphisms (SNPs) in different 
P. falciparum genes, including pfdhfr, pfdhps, pfcrt, and 
pfmdr1. The accumulation of SNPs in these parasites can 
produce in vivo resistance.
It has been demonstrated that the accumulation of 
SNPs in pfdhfr and pfdhps genes increases the levels of 
SP resistance in  vivo [7]. In West and Central Africa, a 
triple mutant genotype of pfdhfr (N51I, C59R, S108N) 
combined with the A437G mutation in the pfdhps gene 
has been related to SP treatment failure [8]. Another 
Fig. 1 Map of Equatorial Guinea. The map shows the Insular Region, where is located the capital of the country (Malabo); and the Continental 
Region between Cameroon and Gabon. Source http://go.grolier.com/atlas?id=mgaf016a/72/62272‑004‑F1EF86B4.jpg
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significant predictor of SP treatment failure is the quin-
tuple mutant genotype, which includes the pfdhfr tri-
ple mutant combined with the pfdhps double mutant 
(A437G + K540E) [9].
New terms have been recently introduced to classify 
SP-resistant parasites. These terms distinguish parasites 
that are “partially resistant”, “fully resistant”, and “super 
resistant”. The parasites are classified based on the com-
bination of mutations they carry in the two genes, pfd-
hfr and pfdhps. In particular, the combination of triple 
mutant, pfdhfr N51I, C59R, S108N and pfdhps A437G, 
confers partial resistance; the combination of triple 
mutant, pfdhfr N51I, C59R, S108N and double mutant, 
pfdhps A437G, K540E, confers full resistance; and the 
combination of triple mutant, pfdhfr N51I, C59R, S108N 
and triple mutant, pfdhps A437G, K540E, A581G, con-
fers super resistance [10]. These different combinations 
of mutations, and therefore the three different genotypes, 
can affect the results of intermittent prophylactic treat-
ment (IPT) in infected pregnant women and children. 
Moreover, SNPs in pfmdr1 (the P. falciparum multi-drug 
resistance gene) at positions N86Y and D1246Y were 
associated with modulating parasite tolerance and sus-
ceptibility to a number of anti-malarial drugs, including 
quinine, AQ, CQ (but here, it plays a secondary role), 
mefloquine, and lumefantrine [11]. Furthermore, ampli-
fications of the pfmdr1 gene may cause resistance to 
artesunate.
Mutations in the pfcrt gene at codons 72, 74, 75, and 
76 were associated with P. falciparum resistance to CQ. 
Moreover, the K76T mutation was associated with AQ 
resistance. There is evidence that AQ may induce selec-
tion of the pfcrt T76 and pfmdr1 Y86 mutant alleles. 
That result may provide some insight into the previously 
observed cross-resistance between CQ and AQ in  vivo. 
Mutant pfcrt T76 and pfmdr1 Y86 alleles are currently 
used as molecular markers of CQ resistance. They may 
also be useful for monitoring the spread of AQ resistance 
in areas of low AQ resistance, such as west Africa [11].
Several studies have investigated molecular markers 
related to resistance to different anti-malarial drugs in 
Equatorial Guinea. The most recent studies focused on 
the detection of mutations in pfmdr1 and pfcrt prevalent 
in Bioko Island [12, 13]. In Bioko Island, the Ministry of 
Health has introduced the use of SP as an IPT (IPT-SP), 
but currently, IPT-SP is not extensively used in the main-
land. In the new National Plan against Malaria of Equa-
torial Guinea, the health authorities plan to introduce an 
IPT-SP approach in the mainland. Therefore, it is neces-
sary to examine the current prevalence of mutations in P. 
falciparum genes related to SP resistance in this area, to 
enable assessments of the level of success or failure after 
implementation.
The P. falciparum samples used in this study were col-
lected from the mainland of Equatorial Guinea. They 
were collected in two previous studies conducted in 
this region; one was a survey of clinical knowledge and 
skills regarding malaria; the other was a study on the 
prevalence of malaria [4, 14]. The present study aimed to 
investigate the level of mutations related to resistance to 
different anti-malarial drugs in the P. falciparum genes, 
pfdhfr, pfdhps, pfmdr1, and pfcrt, in the Continental 
Region of Equatorial Guinea, after 8 years of implement-
ing artesunate combination therapies as the first-line 
treatment for malaria (artesunate/AQ).
Methods
Area of study and samples
It was carried out a survey in the District of Bata, Con-
tinental Region of Equatorial Guinea, located between 
Cameroon and Gabon, whose capital city is Bata (Fig. 2). 
This region is divided into four provinces, Centro Sur, 
Kie-Ntem, Litoral, and Wele-Nzas. It has a tropical cli-
mate with two dry seasons (December–March and 
June–September), alternating with two rainy seasons 
(March–June and September–December). The mean 
daily maximum and minimum temperatures range 
between 29–32 and 19–22 °C, respectively.
Samples were obtained during a cross–sectional sur-
vey study, which was carried out in June–August 2013 
in the Bata district (Litoral Province), called “PREVA-
MAL”. That project provided baseline data on malaria 
prevalence, a molecular characterization of Plasmodium 
and malaria vectors in the area, and information on the 
knowledge, practices, and attitudes of the general popu-
lation [4, 14]. Sampling was carried out with a multistage, 
stratified cluster strategy. Rural villages and urban neigh-
bourhoods were randomly selected with a probability 
proportional to their size to improve accuracy in sample 
design. A total of 1043 and 698 people living in urban and 
rural settings, respectively, were recruited for PREVA-
MAL study [4] (Fig. 2).
Finger blood samples were taken, and malaria was 
diagnosed with rapid malaria tests and microscopy. 
Moreover, blood samples were spotted on Whatman 
903™ blood samples were spotted on Whatman 903™ 
paper (GE Healthcare Bio-Sciences Corp.) for further 
molecular studies. For example, diagnoses were vali-
dated with semi-nested multiplex PCR (to quality con-
trol the microscopy and rapid diagnoses; and mutations 
were analysed in different P. falciparum genes that might 
be related to resistances to different anti-malarial drugs. 
For the present study, 244 samples (102 from the urban 
area and 142 from the rural area) were selected to ana-
lyse mutations in different P. falciparum genes that were 
related to anti-malarial drug resistance.
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DNA extraction and molecular analysis
DNA was extracted from blood samples (spotted on fil-
ter papers) with commercial kits (Speedtools tissue DNA 
Extraction Kit, Biotools, Spain). Each diagnosis was car-
ried out with the semi-nested multiplex PCR method, as 
described previously [15, 16].
Samples that were positive for malaria in the semi-
nested multiplex PCR, due to P. falciparum, were 
selected to screen for mutations related to drug resist-
ance in the following P. falciparum genes: pfdhfr, pfdhps, 
pfmdr1, and pfcrt. Mutation screening was performed 
as previously described in Maryland University Proto-
cols by Dr. C. Plowe (http://medschool.umaryland.edu/
malaria/protocols/), with minor modifications. Briefly, 
first a nested PCR protocol was performed. Then, PCR 
products were separated with electrophoresis on a 2% 
agarose gel, and stained with ethidium bromide. With 
an ultraviolet transilluminator, were identified the cor-
rect genes, based on size. Next, was isolated the bands, 
and digested with different restriction enzymes to 
analyse restriction-fragment length polymorphisms 
(RFLPs). Each mutation point in each of the genes 
requires a different enzyme (New England BiolabsR 
Inc.) to know whether or not there is a mutation in that 
position.
Haplotypes of pfdhfr and pfdhps genes that exhibited 
a combination of mutations in both genes were classi-
fied previously by Naidoo et  al. [10]. The first class was 
a quadruple mutant considered partially resistant (pfd-
hfr 51I59R/108N +  pfdhps 437G); the second class was 
a quintuple mutant considered fully resistant (pfdhfr 
51I/59R/108N + pfdhps 437G/540E); and the third class 
was a sextuple mutant considered super resistant (pfdhfr 
51I/59R/108N  +  pfdhps 437G/540E/581G). The haplo-
types of the other genes studied comprised one double 
mutation in a single gene: 86Y/1246Y pfmdr1; and a com-
bination of two single mutations in different genes: 86Y 
pfmdr1 + 76T pfcrt.
Fig. 2 Map of the Mainland of Equatorial Guinea. It appears in red the limit of the Litoral Province, whose Capital is Bata. The sampling was carried 
out in Bata (urban area), and in different rural settings (black points in the map). Source https://www.cartedumonde.net, modified
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Statistical analysis
The frequencies and 95% confidence interval (CI) were 
used for categorical variables. Distribution of the SNPs 
in every gene and their combinations in urban and rural 
settings were assessed by Chi square test or Fisher’s exact 
test. The level of statistical significance was set at a value 
of p ≤ 0.05. Statistical analyses were performed using the 
software package SPSSv.15.0.
Ethics
This study was approved by the Minister of Health and 
Social Welfare of Equatorial Guinea (MINSABS) and the 
Ethics Committee of the Spanish National Health Insti-
tute, Carlos III (CEI PI 22_2013-v3). Written informed 
consent for participation in the study was obtained from 
the caregivers interviewed and from the heads of the 
households.
Results
Prevalence of SNPs in pfdhfr and pfdhps genes
It was examined the individual mutations in each codon 
of the pfdhfr gene. The 51I mutation appeared in 97 and 
99% of urban and rural samples, respectively, and the 
overall prevalence was 98% (95% CI 96.24–97.76). The 
108N mutation was found in 99 and 100% of urban and 
rural samples, respectively, and the overall prevalence 
was 99% (95% CI 97.75–100.25). Both these mutations 
had a prevalence close to 100%. The prevalence of the 
59R mutation was 72% (95% CI 66.37–77.63). This muta-
tion was found significantly more frequently in rural 
(79%) than in urban (63%) settings (p = 0.003). The 164L 
mutation was found in only two samples from rural vil-
lages, at a frequency of 1.4% (95% CI −0.25 to 2.25) 
(Table 1). This was the first report of the detection of this 
mutation in West Africa. In Fig.  3 appears the result of 
the RFLPs for the study of the position 164 in pfdhfr gene 
(restriction with the Psi I enzyme). When the sample is 
non-digested, it indicates that has a mutation in 164 posi-
tion (164L).
In the pfdhps gene, the 437G mutation appeared in 
close to 90% of samples. Significant differences were 
found between urban and rural areas in the percentages 
of samples that harboured the 540E (p = 0.003) and 581G 
(p =  0.039) mutations. The overall prevalences of these 
mutations were 17% (95% CI 12.29–21.71) and 10% (95% 
CI 6.24–13.76), respectively.
The combinations of multiple mutations found in sin-
gle genes and in both genes, are shown in Table  2. The 
triple pfdhfr mutant (51I/59R/108N, haplotype IRN), 
which was related to SP resistance in  vitro and in  vivo, 
appeared in 62% and 78% of urban and rural samples, 
respectively (p = 0.007). It was observed another combi-
nation that included a mutation (164L), recently detected 
in this area; this combination, 51I/59R/108N/164L, 
haplotype IRNL was detected in 1.4% of samples from 
rural settings. It is important to monitor the spread and 
increase of this single mutation, to enable the prevention 
of potential combinations of this mutation with others.
In this study, was detected the partially resistant 
(51I/59R/108N/437G, haplotype IRNG) at a similar per-
centage in urban (57%) and rural settings (52%), and the 
overall prevalence was 54% (95% CI 47.75–60.25). The 
Table 1 SNPs of each gene by area
It shows the prevalence of each point of mutation (SNPs) in each gene of P. falciparum studied, in urban and rural settings
≤0.05 is taken as significance value
Codon Mutation Urban area n = 102 
N (%)
Rural area n = 142 
N (%)




 pfdhfr N51I 51I 99 (97) 141 (99) 0.174 240 (98) 96.24 to 97.76
 pfdhfr C59R 59R 64 (63) 113 (79) 0.003 177 (72) 66.37 to 77.63
 pfdhfr S108N 108N 101 (99) 142 (100) 0.209 243 (99) 97.75 to 100.25
 pfdhfr I164L 164L 0 2 (1.4) 0.337 2 (0.8) −0.25 to 2.25
pfdhps
 pfdhps S436A 436A 16 (31) 26 (18) 0.592 42 (17) 12.29 to 21.71
 pfdhps A437G 437G 94 (92) 126 (89) 0.375 220 (90) 86.24 to 93.76
 pfdhps K540E 540E 9 (9) 33 (23) 0.003 42 (17) 12.29 to 21.71
 pfdhps A581G 581G 15 (15) 9 (6) 0.039 24 (10) 6.24 to 13.76
pfmdr1
 Pfmdr1 N86Y 86Y 68 (67) 104 (73) 0.266 172 (70) 64.25 to 75.75
 Pfmdr1 D1246Y 1246Y 2 (2) 7 (5) 0.224 9 (4) 1.54 to 6.46
pfcrt
 pfcrt K76T 76T 28 (27) 46 (32) 0.407 74 (30) 24.25 to 35.75
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fully resistant (51I/59R/108N/437G/540E, haplotype 
IRNGE) appeared in 5 and 16% of urban and rural sam-
ples, respectively (p =  0.006). The overall prevalence of 
the full resistance genotype was 11% (95% CI 7.07–14.93). 
The super resistant (51I/59R/108N/437G/540E/581G, 
haplotype IRNGEG) was detected in 2 and 3% of urban 
and rural samples, respectively, and the overall preva-
lence was 2.4% (95% CI 0.48–4.32). We also found other 
combinations with significant differences between 
urban and rural areas. It was found the quadruple 
Fig. 3 Electrophoresis in agarose gel of the RFLPs for position 164 in pfdhfr. Electrophoresis of the result of the digestion with the PsiI enzyme. It can 
be seen that in two samples (12N and 119_02_03) there is no digestion, indicating that the position 164 is mutated (164L) and the enzyme cannot 
recognize its target. When is digested the fragment of 254 bp, appear two fragments 214 and 42 bp. C− Control of “non‑digested”, fragment of PCR 
(size 254 bp) that was not subjected to digestion with PsiI enzyme. C+ Control of digestion, fragment of the PCR that always is digested with the PsiI 
enzyme
Table 2 Combination of mutations related with the resistance in P. falciparum
It shows the prevalence of the different combinations of mutations in each gene (pfdhfr and pfmdr1), and the combination between different genes of P. falciparum: 
pfdhfr ± pfdhps
≤0.05 is taken as significance value
a Partially resistant pfdhfr 51/59/108 + pfdhps 437 (51/59/108/437)
b Fully resistant pfdhfr 51/59/108 + pfdhps 437/540 (51/59/108/437/540)
c Super resistant pfdhfr 51/59/108 + pfdhps 437/540/581 (51/59/108/437/540/437) and the combination in pfmdr1 ± pfcrt












 51/59/108 IRN 3 63 (62%) 110 (78) 0.007 173 (71) 65.31 to 76.69
 51/59/108/164 IRNL 4 0 2 (1.4) 0.168 2 (0.8) −0.32 to 1.92
pfdhfr + pfdhps
 a51/59/108/437 IRNG 4 58 (57) 74 (52) 0.462 132 (54) 47.75 to 60.25
 51/59/108/540 IRNE 4 5 (5) 24 (17) 0.004 29 (12) 7.92 to 16.08
 51/59/108/581 IRNG 4 11 (11) 6 (4) 0.047 17 (7) 3.8 to 10.2
 51/59/108/164/437 IRNLG 5 0 1 (1) 0.58 1 (0.4) −0.39 to 1.19
 b51/59/108/437/540 IRNGE 5 5 (5) 23 (16) 0.006 28 (11) 7.07 to 14.93
 51/59/108/437/581 IRNGG 5 11 (11) 3 (2) 0.004 14 (6) 3.02 to 8.98
 c51/59/108/437/540/581 IRNGEG 6 2 (2) 4 (3) 0.67 6 (2.4) 0.48 to 4.32
pfmdr1
 86/1246 YY 2 1 (1) 3 (2) 0.492 4 (2) 0.24 to 3.76
pfmdr1 + pfcrt
 86/76 YT 2 20 (20) 34 (24) 0.4208 54 (22) 16.8 to 27.2
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mutant (pfdhfr 51I/59R/108N + pfdhps 540E; haplotype 
IRNE) in 5 and 17% of urban and rural samples, respec-
tively (p  =  0.004). Another quadruple mutant (pfd-
hfr 51I/59R/108N  +  pfdhps 581G; haplotype IRNG) 
in 11 and 4% of urban and rural samples, respectively 
(p  =  0.047). It was also found the quintuple mutant 
(pfdhfr 51I/59R/108N  +  pfdhps 437G/581G; haplo-
type IRNGG) in 11 and 2% of urban and rural samples, 
respectively (p = 0.004).
Prevalence of SNPs in pfmdr1 and pfcrt genes
The mutation, pfmdr1 86Y, appeared at similar frequen-
cies (67 and 73%) in urban and rural samples, respec-
tively. The overall prevalence of this mutation was 70% 
(95% CI 64.25–75.75). Another mutation in the pfmdr1 
gene, 1246Y, was less frequently detected than the 86Y 
mutation (2 and 5% in urban and rural areas, respec-
tively). The overall prevalence of this mutation was 4% 
(95% CI 1.54–6.46) (Table 1).
The mutation in pfcrt, 76T, appeared at a similar fre-
quency in both areas (27% in urban and 32% in rural 
areas). The overall prevalence of this mutation was 30% 
(95% CI 24.25–35.75).
The combinations of different mutations in pfmdr1 
and pfmdr1  +  pfcrt are summarized in Table  2. The 
double mutation in pfmdr1 (86Y  +  1246Y; haplotype 
YY) occurred in 1% and 2% of urban and rural samples, 
respectively. The overall prevalence was 2% (95% CI 
0.24–3.76). Finally, the combination of single mutations 
in two genes (pfmdr1 86Y  +  and pfcrt 76T; haplotype 
YT), which was related to resistance to CQ and AQ, was 
found in 20 and 24% of urban and rural samples, respec-
tively; the overall prevalence of this combination was 22% 
(95% CI 16.8–27.2).
Discussion
In the current study, a high level of mutations was found 
in P. falciparum genes related to anti-malarial drug resist-
ance in samples from the mainland of Equatorial Guinea. 
This high prevalence may limit the use of some anti-
malarial drugs for treating malaria or for IPTs.
When a country withdraws a given treatment, due to 
the level of drug resistance, over a given period of time, 
the sensitive parasite population increases its presence 
with respect to the resistant population [17]. Further-
more, when a country does not change the treatment 
policy at the time drug resistance appears, the mutations 
remain fixed in the population of parasites and the tar-
get drugs, like SP, cannot be used, either as treatments 
or as prophylactics. In the present study, two P. falcipa-
rum mutations were detected that had a prevalence very 
close to 100% (108N and 51I). These high prevalences 
could mean that these mutations are fixed in the parasite 
population, which implied that SP would have limited 
effectiveness as an IPT in this area of the country. On 
the other hand, it has been reported the first detection 
in West Central Africa of the 164L mutation in pfdhfr. 
This mutation could have important implications for 
the effectiveness of SP as an IPT, both in children under 
5 years old and pregnant women, even though presently, 
the mutation was detected at a very low frequency. These 
mutations should be monitored to ensure that the fre-
quency does not increase in the parasite population.
The 581G mutation in pfdhps has an important mod-
ulatory role in resistance. When the frequency of this 
mutation is above 10%, IPT with SP cannot protect preg-
nant women from delivering low birth weight infants 
[18]. On the other hand, the WHO recommended that, 
in areas where the frequency of the pfdhps 540 mutation 
is 50%, IPT should not be implemented, because it could 
fail. In the mainland of Equatorial Guinea, the 581G 
mutation was detected at 15% in the urban area. For this 
reason, the National Malaria Control Programme and 
the Ministry of Health and Social Welfare of Equatorial 
Guinea should implement measures in the Bata District 
to control the spread of these mutations. Moreover, it 
is important to prevent the pfdhps 540E mutation from 
reaching 50% frequency, to avoid reducing the efficiency 
of IPT-SP.
All three parasite genotypes that confer partial, full, and 
super resistance [10] were detected in the Bata district. 
The super resistant genotype has raised the threshold of 
drug tolerance among parasites, which has important 
implications for the use of SP. The detection of the super 
resistant genotype indicates that the SP combination has 
continued to be used with frequency in this area, despite 
the fact that the health authorities have withdrawn SP 
from the national treatment guidelines.
Importantly, it was detected the presence of the 164L 
mutation in combination with the triple 51/59/108 
mutant, although at low frequency (1.4%). It is known 
that this mutation, alone or in combination with other 
mutations in pfdhfr and pfdhps, is related to high SP 
resistance. Due to the potency of this mutation, an effec-
tive control system is required to prevent its spread.
Based on the findings of the high prevalence of 
mutations in the pfdhfr and pfdhps genes, it is recom-
mended that the SP combination should not be used as 
a treatment in Equatorial Guinea. Moreover, any further 
increases in the mutation levels may require us to recon-
sider the use of ITP-SP in children under 5 years of age 
and pregnant women, in this area of the country.
When the prevalence of the super resistant genotype 
reaches 10%, it is considered sufficiently high to have an 
effect on the population [10]. In the present study, was 
found this genotype at frequencies of 2 and 3% in urban 
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and rural samples, respectively. Thus, the prevalence was 
well below 10%. Nevertheless, the country should put 
into place measures that can control the rise of this muta-
tion in the population.
In Bioko Island, the Ministry of Health has introduced 
the use of IPT-SP. Currently, IPT-SP is not extensively 
used in the mainland; however, the health authorities 
want to introduce IPT-SP in the mainland region, with 
the new National Plan Against Malaria of Equatorial 
Guinea. The presence of these mutant parasites makes 
it necessary to increase the control over the population 
at risk, children under 5 years old and pregnant women, 
that are within the IPT regimen, to avoid a possible 
reduction in drug efficacy for preventing the disease.
The first time the WHO considered the resistance to 
SP combination was in 2010 in a technical study. At that 
time, they recommended that the presence of a 540 muta-
tion in pfdhps (one of the SNPs in the quintuple mutant, 
or fully resistant genotype) should serve as an indicator 
to predict or to decide where IPT could be established for 
children under 5 years old [10]. The present study found 
a high prevalence (16%) of the fully resistant genotype in 
the rural area.
The 540 mutation in pfdhfr is very common in East 
Africa, where its prevalence was 100% in 2004 [19]. In 
West Africa, the prevalence has been relatively low; 
6.25% in Gabon (2007), 0.8% in Congo (2004), 11% in Sao 
Tomé, 24% in Nigeria, and 2% in Cameroon [20]. In this 
study, the prevalence was low in urban samples (9%) but 
it reached 23% in rural samples. It is important to note 
that this prevalence was more similar to the prevalence 
in Nigeria than to the prevalence in Cameroon, which is 
the neighbouring country. A potential explanation might 
be that, in Cameroon, from 2009, they adopted a restric-
tion on SP, to be used only in IPT (in pregnant women 
and children under 5  years old), and they withdrew the 
use of SP as malaria treatment. In contrast, SP treatment 
has not been controlled in the area of Equatorial Guinea 
included in the present study [21].
In areas with a high level of SP resistance, like North-
ern Tanzania, resistance has been related to the emer-
gence of the super resistant genotype [10]. The presence 
of this sextuple genotype was shown to be related to the 
loss of protective efficacy with IPT in children and preg-
nant women. The frequency of this genotype appeared to 
increase in cases of placental malaria in women that had 
received IPT [22]. Currently, the prevalence of the super 
resistant genotype in the mainland of Equatorial Guinea 
remains low; but, once again, it is very important to con-
trol the use of SP and ensure it is used exclusively for 
IPT. Furthermore, in the mainland region of Equatorial 
Guinea, SP should never be used as a treatment, either 
alone or in combination with another treatment.
The combined pfdhfr 51/59/108/164 mutation is com-
mon in South America and East Africa, and it has been 
related to high SP resistance. It is considered fully resist-
ant, when it appears together with the pfdhps 437/540 
mutation [20]. In the mainland of Equatorial Guinea, this 
genotype pfdhfr 51/59/108/164 was found in only 2 sam-
ples from rural settings. The health authorities should 
be alerted with this finding; increases in these mutations 
and their spread should be controlled early. The authori-
ties should exhaustively control the withdrawal of SP as 
a treatment, and limit the use of SP exclusively to IPT 
implementations in children under 5 years old and preg-
nant women.
Some resistance genes were detected in Equatorial 
Guinea at frequencies similar to those reported for Cam-
eroon by Chauvin et  al. [20], but other mutations were 
found for the first time in this part of Africa. In Equatorial 
Guinea, the pfdhfr 51/59/108 genotype was observed less 
frequently (71%) than in Cameroon (94%), but the partial 
resistant genotype (pfdhfr 51/59/108 + pfdhps 437) was 
the most common. On the other hand, the super resistant 
genotype (pfdhfr 51/59/108 + pfdhps 437 + 540 + 581) 
was not detected in Cameroon, but was detected in 
Equatorial Guinea, although at low frequency. Impor-
tantly, the present study was the first to detect the super 
resistant genotype in this area of Africa. A previous study 
conducted in this district [14] found that SP use had been 
continued, as a treatment alone or in combination with 
AQ, despite warnings that these treatments should be 
discontinued to avoid increasing SP resistance. Because 
SP was not reserved exclusively for IPT, its use may have 
induced a high level of mutations, which led to the SP 
resistance detected in this area of Equatorial Guinea.
The mutations found in PF genes pfmdr1 and pfcrt 
were associated with resistance to other anti-malarial 
drugs, including artesunate, AQ, lumefantrine. This study 
was the first to describe these mutations in the mainland 
of Equatorial Guinea. In 2014 and 2015, Li et al. analysed 
the pfmdr1 and pfcrt genes in Bioko Island (Equato-
rial Guinea). They detected an 80% prevalence of the 76 
pfcrt mutation in Bioko Island [12], but in the Bata dis-
trict, the prevalence was around 30%. This mutation is 
related to CQ resistance. This treatment was successfully 
withdrawn by the authorities in this part of Equatorial 
Guinea, which could explain the differences in prevalence 
between this part of the country and Bioko Island or 
neighbouring countries, like Cameroon (83%) and Gabon 
(70%) [23, 24].
The combination of the 86Y and 1246Y mutations in 
the pfmdr1 gene was associated with reduced suscepti-
bility to artesunate/AQ [6], which is the first-line treat-
ment for uncomplicated malaria in Equatorial Guinea, 
according to the National Therapeutic Guidelines. It is 
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known that the pfmdr1 86Y mutation is related to resist-
ance to CQ and AQ, and the 1246Y mutation is related 
to quinine resistance [6]. In this study, the prevalence of 
the combination of both mutations (86Y +  1246Y) was 
2% in the parasite population. Based on this relatively low 
prevalence, currently, the use of artesunate/AQ as a first-
line treatment is not endangered in Equatorial Guinea. 
In studies carried out in Southeast Asia, the presence of 
mutations in both codons (86 and 1246) has been related 
to resistance to CQ, mefloquine, and AQ [25, 26]. Muta-
tions in pfmdr1 were also associated with an increase in 
resistance to artesunate; therefore, it is estimated that 
control of these mutations will serve to monitor the 
resistance to artesunate in a given region [26].
The combination of mutations in pfcrt and pfmdr1 
(pfcrt 76T + pfmdr1 86Y) found in the Bata district are 
related to AQ resistance. The most recent studies on ther-
apeutic efficacy carried out in the country suggested that 
artesunate/AQ retained nearly 95% of an effect (unpub-
lished data); thus, currently, the presence of these muta-
tions may not compromise the effectiveness of treatment. 
However, it becomes necessary to introduce the study of 
all these mutations in the National Malaria Control Pro-
gramme taking in account the surveillance of mutations 
and the spread of them. The present study provided an 
update on the prevalence of mutations that confer resist-
ance to different anti-malarial drugs (SP, AQ, CQ, meflo-
quine, artesunate) in the mainland of Equatorial Guinea. 
Although this study was carried out only in the mainland, 
our findings indicated that the prevalence of SNPs was 
different than those reported for Bioko Island and neigh-
bouring countries, such as Cameroon and Gabon. A new 
mutation (164L) was detected in two samples. The pres-
ence of this mutation appeared to be a local phenomenon 
because, at the time the samples were collected, patients 
were excluded from the study if they had been in another 
endemic country in the month prior to taking the sam-
ple. Also, the 540E mutation was previously only found 
in isolates from eastern Africa, and in 2015, it was found 
in Cameroon [20]. Finally, it was detected the three geno-
types described by Naidoo and Roper (partially, fully, and 
super resistant genotypes). These findings call for contin-
ued efforts to prevent the spread of highly drug resistant 
parasites.
Conclusions
This study showed that this area had high levels of muta-
tions in the P. falciparum genes, pfdhfr and pfdhps, which 
were related to resistance to SP treatment. The 164L 
mutation, which was associated with high resistance to 
SP, was detected for the first time in this area.
The high number of mutations detected in this area 
of the country could be linked to the unsuccessful 
withdrawal of the SP treatment, used alone or in combi-
nation with other anti-malarial drugs. This unsuccessful 
withdrawal could affect the efficacy of IPT for children 
under 5  years old and for pregnant women. It was also 
observed mutations in pfmdr1 and pfcrt, which were 
related to resistance to AQ, CQ, and artesunate. How-
ever, a review of the studies on therapeutic effectiveness 
carried out in this country indicated that these mutations 
did not affect the effectiveness of first-line treatment with 
artesunate/AQ.
These results demonstrated the urgency of the neces-
sity to block the use of SP as treatment in this area of the 
country. The SP combination should be reserved exclu-
sively for use in IPT for children under 5  years old and 
pregnant women. To avoid the use of drugs prohibited by 
the public health authorities, it will be necessary to pro-
vide the health centres and hospitals with an alternative 
first-line treatment for malaria, and extend its use to the 
entire the region. This strategy will limit increases in the 
number of mutations, the occurrence of new mutations, 
and particularly, the spread of mutations, to protect the 
population more effectively.
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